1.
Medchemcomm
; 8(4): 771-779, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30108796
RESUMO
Small molecule DGAT2 inhibitors have shown promise for the treatment of metabolic diseases in preclinical models. Herein, we report the first toxicological evaluation of imidazopyridine-based DGAT2 inhibitors and show that the arteriopathy associated with imidazopyridine 1 can be mitigated with small structural modifications, and is thus not mechanism related.